Objective: To test whether extracorporal shock wave therapy (ESWT) has an effect in the treatment of Peyronie’s disease.Methods: 22 patients with Peyronie’s disease and previous unsuccessful oral drug therapy were treated with ESWT in a prospective design with a follow–up of at least 3 months; 23 age–matched patients without previous therapy received oral placebo drug for 6 months daily as control. The standard follow–up included palpation, ultrasound, autophotography and evaluation of symptomatology based on a symptom score. The shock waves were applied under ultrasound guidance using the ‘Storz Minilith SL1’ lithotripter.Results: The results show a significant decrease in penile curvature in the patients treated with ESWT. Concerning the decrease in pain, subjective improvement and improvement in the quality of sexual intercourse, there was no significant difference to the case–control group. The inhomogeneity of the 2 groups may influence these results due to the questionable varying natural history.Conclusions: A prospective, controlled multicenter study with standardized parameters (concerning technique and patients) is urgently required to test the effect of ESWT.

Keywords:
Peyronie’s disease, Extracorporal shock wave therapy, Case control
1.
Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF: The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997;157:276–281.
2.
Weidner W, Schroeder–Printzen I, Weiske WH: Sexual dysfunction in Peyronie’s disease: An analysis of 222 patients without previous local plaque therapy. J Urol 1997;157:325–328.
3.
De la Peyronie F: Sur quelques obstacles qui s’opposent à l’éjaculation naturelle de la semence. Mém Acad R Chir 1743;1:425–434.
4.
Somers KD, Dawson DM: Fibrin deposition in Peyronie’s disease plaque. J Urol 1997;157: 311–315.
5.
El–Sakka AI, Lue TF: Peyronie’s disease. Curr Opin Urol 1998;8:203–209.
6.
Weidner W, Schroeder–Printzen I, Rudnick J, Krause W, Weiske WH, Drawz B, Rebmann U, Pastermadjeff L, Kallerhoff M, Lenk S, Sperling H, Kliesch S, Schnittker J, Aulitzky W: Randomized prospective placebo–controlled therapy of Peyronie’s disease (IPP) with Potaba® (aminobenzoate potassium). J Urol 1999;161(suppl):205.
7.
Levine LA, Lenting EL: A surgical algorithm for the treatment of Peyronie’s disease. J Urol 1997;158:2149–2152.
8.
Chaussy C, Eisenberger F, Wanner K, Forssmann F, Hepp W, Schmiedt E, Brendel W: The use of shock waves for the destruction of renal calculi without direct contact. Urol Res 1976; 4:175–181.
9.
Iro H, Schneider H, Födra C, Waitz G, Nitsche N, Heinritz HH, Benninger J, Ell C: Shockwave lithotripsy of salivary gland stones. Lancet 1992;339:1333–1336.
10.
Dahmen GP, Haupt G, Haist J, Loew M, Lüssenhop S, Rompe JD, Schleberger R: Die Extrakorporale Stosswellentherapie in der Orthopädie. Indikationen, Techniken, bisherige Ergebnisse und Empfehlungen. Konsensus–Papier der Arbeitsgruppe Orthopädische Stosswellentherapie, 2. Konsensus–Workshop der Deutschen Gesellschaft für Stoßwellenlithotripsie, Schloss Weitenburg, 1995.
11.
Haupt G: Stosswellen in der Orthopädie. Urologe A 1997;36:233–238.
12.
Haupt G: Use of extracorporal shock waves in the treatment of the pseudarthrosis, tendinopathy and other orthopedic diseases. J Urol 1997; 158:4–22.
13.
Heist J, von Keitz–Steeger D: Stosswellentherapie knochennaher Weichteilschmerzen – Ein neues Behandlungskonzept; in Chaussy C, Eisenberger D, Jocham D, Wilbert D (eds): Die Stosswelle – Forschung und Klinik. Tübingen, Attempto, 1995, pp 162–168.
14.
Butz M, Teichert HM: Treatment of Peyronie’s disease (PD) by extracorporal shockwaves (ESW). J Urol 1998;159(suppl):118.
15.
Baumann M, Tauber R: Induratio penis plastica – Extrakorporale piezoelektrische Stosswellentherapie als neuer Therapieansatz. Akt Urol 1998;29:1–5.
16.
Colombo F, Mantovani F, Patelli E, Pozzoni F, Pisani E: Shock waves in la Peyronie’s disease: Two years experience (abstract 494). Eur Urol 1999;35(suppl 2):124.
17.
Gianneo E, Nespoli R, Conti G, Comeri G: La Peyronie’s disease (IPP) and extracorporal shock waves therapy (ESWT): Our experience. J Urol 1999;161(suppl):205.
18.
Michel MS, Braun P, Sazova O, Musial A, Köhrmannn KU, Alken P: Shock–wave therapy for the treatment of Peyronie’s disease: First clinical investigation for the objective determination of deviation improvement by means of artificial erection. J Urol 1999;161(suppl):262.
19.
Sautter T, Bangerter U, Tullio S, Hauri D: Extracorporal shockwave (ESW) as a new effective treatment in Peyronie’s disease. Eur Urol 1999;35:(suppl 2):124.
20.
Weidner W, Müller S: Stellungnahme zur ESWT bei Induratio penis plastica. Urologe A 1998;37:107.
21.
Colombo F, Serrago M, Esposito N, Patelli E, Mantovani F, Pisani E: Shock waves in la Peyronie’s disease: The preliminary report. J Urol 1998;159(suppl):119.
22.
Hauck EW, Altinkilic BM, Schroeder–Printzen I, Ludwig M, Weidner W: The extracorporal shock–wave in treatment of Peyronie’s disease – First results of a case controlled approach. Eur Urol 1999;35(suppl 2):68.
23.
Furlow WL, Swanson HE, Lee RE: Peyronie’s disease: A study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975;114:69–71.
24.
Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990;144: 1376–1379.
25.
Poutasse EF: Peyronie’s disease. J Urol 1972; 107:419–422.
26.
Kelâmi A: Autophotography in evaluation of functional penile disorders. Urology 1983;21: 628–629.
27.
Bähren W, Stief CG: Intrakavernöse Pharmakontestung – SKAT–Test; in Bähren W, Altenwein JE (eds): Impotenz. Stuttgart, Thieme 1988.
28.
Byström J, Rubio C: Induratio penis plastica. Peyronie’s disease. Clinical features and etiology. Scand J Urol 1975;10:12–20.
29.
Rosen RC, Riley A, Wagner G, Osterloh IH; Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–830.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.